RO7268489, Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, RO7268489 Placebo, RO7268489, RO7268489, RO7268489
BP46016
Phase 2 small_molecule active
Quick answer
RO7268489, Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, RO7268489 Placebo, RO7268489, RO7268489, RO7268489 for Progressive Forms of Multiple Sclerosis (PMS) is a Phase 2 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Progressive Forms of Multiple Sclerosis (PMS)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active